Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease

from Venture Capital Access Online: Latest Venture Capital and Private Equity News https://ift.tt/3wT4lta
via IFTTT